I. MODIFIED AGREEMENTS | ||||
Biotech Co.* (Country/Symbol) |
Pharma Co. (Country) (M) |
Change from original agreement |
Disclosed Funding |
Terms/Details (Date) |
Affymetrix Inc. (AFFX) |
GlaxoSmithKline plc (UK) |
Expanded agreement for Affymetrix GeneChip technology |
ND |
The agreement enables GSK research sites to design custom GeneChip arrays on smaller format sizes that will provide them with lower-cost arrays for use in high-throughput settings (9/10) |
Dendreon Corp. (DNDN) |
Kirin Brewery Co. Ltd. (Japan) |
Expanded agreement in which Dendreon will provide extensive clinical development and regulatory support aimed at seeking marketing approval in Asia of Provenge and Mylovenge |
$10 |
Kirin has all rights in Asia, but Dendreon retains all rights in North America and Europe (8/10) |
GeneData AG (Switzerland)* |
Bayer AG (Germany) |
Extended collaboration in microbial genomics by three years |
ND |
Companies will evaluate identified antibiotics to treat infectious diseases (9/17) |
Genome Therapeutics Corp. (GENE) |
Wyeth-Ayerst Laboratories (unit of American Home Products Corp.) |
Extended genomics-based research collaboration through December 2002 |
ND |
The alliance, formed in 1999, is focused on the prevention and treatment of osteoporosis (7/16) |
Lexicon Genetics Inc. (LEXG) |
NV Organon (the Netherlands) |
Renewed and expanded OmniBank Universal agreement to include access to Lexicon's research program to study the physiological in vivo function of genes |
ND |
Lexicon will receive annual technology access fees and research funding from Organon (7/26) |
Metabolex Inc.* |
Pfizer Inc. |
Realigned research partnership, shifting the focus from insulin-resistant genomics to drug targets |
$6 |
The restructuring includes a one-time payment to Metabolex of $6M, and three years of committed funding; Pfizer also will make an undisclosed equity investment in Metabolex (7/2) |
Microcide Pharmaceuticals Inc. (MCDE) |
Schering-Plough Animal Health |
Amended research collaboration and license agreement increasing the level of Schering-funded research at Microcide |
ND |
Collaboration focused on the discovery and development of veterinary antimicrobial drugs (7/26) |
Millennium Pharmaceuticals Inc. (MLNM) |
Aventis Pharmaceuticals Inc. |
Addition of 11 new discovery projects to the year-old $450M collaboration |
$450 |
The additional discovery projects are subject to terms of the original deal, and do not add value otherwise (8/13) |
Molecular Biosystems Inc. (unit of Alliance Pharmaceutical Corp.; ALLP) |
Mallinckrodt Inc. |
Amended agreement concerning the marketing of Optison |
ND |
In the original agreement, Mallinckrodt was to pay MBI a royalty of 5% of net sales of Optison in the U.S. and Europe for as long as Mallinckrodt was marketing the product; under the amended agreement, MBI will receive an immediate cash payment, plus additional unspecified royalties for a two-year period (8/7) |
MorphoSys AG (Germany; Neuer Markt:MOR) |
Bayer AG (Germany) |
Collaboration extended for four more years |
ND |
MorphoSys will generate fully human therapeutic antibodies against up to 10 targets provided by Bayer (7/11**) |
NeoGenesis Drug Discovery Inc.* |
Schering-Plough Corp. |
Expansion of their deal for antivirals |
$25 |
NeoGenesis gets a $5M equity investment from Schering-Plough, which also will provide research and development funding of about $4M per year for up to five years (8/6) |
Novavax Inc. (AMEX:NOX) |
King Pharmaceuticals Inc. |
Expanded licensing agreement for Estrasorb |
$6 |
King gains exclusive rights for promotion, marketing and distribution of Estrasorb in Canada and five European countries; agreement calls for a $3M up-front licensing fee for Novavax, an additional $1M upon Estrasorb's Canadian approval and a $2M milestone fee upon the first European approval (7/2) |
Onyx Pharmaceuticals Inc. (ONXX) |
Pfizer Inc. |
Modified agreement that returns some of the rights to ONYX-15 to Onyx |
ND |
Pfizer is returning the rights to ONYX-15 only for those cancers treated by way of direct injections; Onyx will pay all costs associated with the injection efforts and will retain all profits in these applications (8/8) |
QLT Inc. (Canada; QLTI) |
Novartis AG (Switzerland) |
Expanded alliance to co-develop photodynamic therapy with verteporfin to treat skin cancer and other dermatological conditions |
C$15 (US$9.7) |
Novartis will fund future development costs up to C$15M, after which the companies will share development costs and profits; QLT can receive milestones of C$2.5M for the first regulatory filing and approval (7/24) |
Rigel Pharmaceuticals Inc. (RIGL) |
Novartis Pharma AG (Switzerland) |
Expanded deal now calling for Rigel to discover and develop small-molecule compounds that inhibit angiogenesis as a therapy for cancer |
$4 |
The original deal, signed in 1999, focused on five different projects aimed at identifying targets using Rigel's functional genomics technology; Rigel will receive a $4M up-front cash payment, milestones and royalty payments (7/31) |
II. TERMINATED AGREEMENTS | ||||
The Immune Response Corp. (IMNR) |
Agouron Pharmaceuticals Inc. (acquired by Pfizer Inc.) |
Termination of development rights for Remune |
ND |
Agouron returned rights to Remune, an HIV product, back to Immune Response, which regains full rights in the U.S., Europe, Japan and certain other countries (7/6) |
NOTES | ||||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | ||||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
ND = Not disclosed, reported and/or available | ||||
AMEX = American Stock Exchange | ||||
